Skip to main content

Life Sciences

By Adam Ang | 07:44 am | November 13, 2025
Early results show 70% accuracy of AI-assisted detection of unexplained male infertility using Asian IVF data.
By Anthony Vecchione | 04:05 pm | November 12, 2025
The company helps match patients to relevant clinical trials and engages in recruitment for biopharma partners.
By Anthony Vecchione | 04:42 pm | November 10, 2025
The company recently presented clinical data at the European Society for Medical Oncology Congress for an investigational drug that displayed anti-tumor activity and a good safety profile.
By Adam Ang | 08:05 am | November 10, 2025
The model also calculates biological ageing and survival patterns to support personalized health risk management.
By Jessica Hagen | 03:01 pm | November 06, 2025
TrumpRx will offer Novo Nordisk's Ozempic and Wegovy for $350 and Eli Lilly and Company's Zepbound and orforglipron, if approved by the FDA, for $346.
By Anthony Vecchione | 01:04 pm | October 31, 2025
The company says it is seeing an increased demand for testosterone hormone treatment.
By Adam Ang | 08:20 pm | October 30, 2025
Also, a startup from Melbourne has raised $1 million in pre-seed funding for its chemotherapy dosing AI.
By Anthony Vecchione | 02:41 pm | October 30, 2025
The funds will be used to increase the company's development into new automated orthopedic indications and deploy its manufacturing model.
By Anthony Vecchione | 04:02 pm | October 28, 2025
The certifications show that the company meets globally recognized standards for medical imaging.
By Anthony Vecchione | 02:33 pm | October 27, 2025
The company will scale its weight loss offerings ahead of generic GLP-1s coming to the Canadian market in 2026.